UNC School of Medicine, Division of Hematology

Chapel Hill, North Carolina 27599

1 studies enrolling now · 1 studies all time

What they study most

Hematologic Malignancies

Studies at this site

• Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML — Recruiting now